University of Miami

Rxmp Therapeutics, Inc.

Yeon S Ahn

Wenche Jy

William J Harrington, Jr

Ravindra Mylvaganam

Lawrence L Horstman

Joaquin J Jimenez

Duncan H Haynes

Rifat Pamukcu

Lawrence L Horstmann

Eugene Ahn

Eugene Room 3300 Sccc Ahn

Joaquin J 7083 Rosenstiel Medical Science Bld Jimenez

The disclosure provides a composition comprising red cell-derived microparticles (RMPs) demonstrating acetylcholine esterase (AchE) activity of less than 350 pmol/min/10particles/uL. The disclosure further provides a method of treating excessive bleeding comprising administering the composition to a subject.

Composition comprising red cell-derived microparticles and method of treating excessive bleeding

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can be considered as universal hemostatic agents. RMP are produced from red blood cells using a high-pressure extrusion membrane shear process and can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.

Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding

Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused by chemotherapy.

Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders

Danazol, a known androgen, is used to (1) correct immune abnormalities associated with hemotologic disorders or (2) treating immune disorders associated with depressed T helper cells, in the invention disclosed.

Treatment of hemolytic anemia with danazol

Treatment of sickle cell disease using danazol.

Method of treating sickle cell anemia with danazol

Calcium (Ca.sup.2+) channel blockers, such as nifedipine and verapamil, are used in the treatment of thromboembolic diseases such as stroke and peripheral vascular occlusive diseases, especially arterial and venous thrombosis, vasculitis, myelofibrosis disease and hemolytic anemias. Such diseases arise from platelet hyperactivation and the Ca.sup.2+ channel blockers restore the platelets to their normal aggregation characteristics. Diagnostic procedures for detecting platelet hyperactivation and defective calcium handling/transport indicative of certain peripheral obstructive diseases using chlorotetracycline as a detectable fluorescent probe as a means of assessing a patient's response to Ca.sup.2+ channel blockers in the therapy of such diseases are also described.

Growing community of inventors

Miami, FL, United States of America

Yeon S Ahn